Mark Borris D. Aldonza

Stanniocalcin-2 (STC2): A potential lung cancer biomarker promotes lung cancer metastasis and progression

Sang-Su Na, Mark Borris D. Aldonza, Hye-Jin Sung et al. · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · 2014 · 62 citations

Medicine, Oncology, Pharmacology +13

Paraoxonase-1 (PON1) induces metastatic potential and apoptosis escape via its antioxidative function in lung cancer cells

Mark Borris D. Aldonza, Yeon Sung Son, Hye-Jin Sung et al. · Oncotarget · 2017 · 44 citations · Full text

Medicine, Cancer Biology, Oncology +15

Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation

Mark Borris D. Aldonza, Ji‐Young Hong, Malona V. Alinsug et al. · Oncotarget · 2016 · 42 citations · Full text

Medicine, Cancer Biology, Pharmacology +14

Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms

Mark Borris D. Aldonza, Jayoung Ku, Ji‐Young Hong et al. · Science Advances · 2020 · 41 citations · Full text

Medicine, Oncology, Pharmacology +17

Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation

Mark Borris D. Aldonza, Ji‐Young Hong, Sang Kook Lee · Experimental & Molecular Medicine · 2017 · 40 citations · Full text

Life Sciences, Oncology, Pharmacology +17